Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2004-09-21
2010-02-09
Haddad, Maher M (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S326000, C530S324000
Reexamination Certificate
active
07659091
ABSTRACT:
An inflammatory peptide can be a marker for cardiac ischemia.
REFERENCES:
patent: 5091404 (1992-02-01), Elgebaly
patent: 5270163 (1993-12-01), Gold et al.
patent: 5403914 (1995-04-01), Elgebaly
patent: 5504013 (1996-04-01), Senior
patent: 5606027 (1997-02-01), Elgebaly
patent: 5622871 (1997-04-01), May et al.
patent: 6235241 (2001-05-01), Catt et al.
patent: 6399398 (2002-06-01), Cunningham et al.
patent: 6670138 (2003-12-01), Gonzalez-Zulueta et al.
patent: 2005/0137481 (2005-06-01), Sheard et al.
patent: WO 91/19813 (1991-12-01), None
patent: WO 92/05285 (1992-04-01), None
patent: WO 92/14843 (1992-09-01), None
patent: WO 03/074069 (2003-09-01), None
Trueba et al. (J Bacteriology 1992 vol. 174, p. 4761-4768.
Trueba et al. Characterization of the periplasmic flagellum proteins of Leptospira interrogans. J. Bacteriol. 174 (14): 4761.1992.
Elgebaly et al. Partial purification of a novel cardiac-derived neutrophil checotactic factor: Nourin-1. Circulation. 1993, 88:1-240 (Abstract).
Burgess, et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. J Cell Biol. 111:2129-2138, 1990.
Alpert, J.S., et al. “Myocardial Infarction Redefined—A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redifinition of Myocardial Infarction”J. Am. Coll. Cardiol.2000; 36; 959-69.
Boersma, E., et al. “Platelet glycoprotein IIb/IIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials”Lancet2002: 359: 189-98.
Brennan, M.L., et al. “Prognostic Value of Myeloperoxidases in Patients with Chest Pain”N. Engl. J. Med.2003; 349:1595-604.
Christenson, R.H., et al. “Characteristics of an Albumin Cobalt Binding Test for Assessment of Acute Coronary Syndrome Patients: A Multicenter Study”Clin. Chem.2001; 47:464-470.
Christenson, R.H. and Azzazy, H.M.E., “Biochemical markers of acute coronary syndromes”Clin. Chem.44, 1855-64, 1998.
Danne, O., et al. “Prognostic Implications of Elevated Whole Blood Choline Levels in Acute Coronary Syndrome”Am. J. Cardiol.2003; 91: 1060-7.
de Lemos, J.A., et. al. “The Prognostic Value of Serum Myoglobin in Patients With Non-ST-Segment Elevantion Acute Coronary Syndromes”J. Am. Coll. Cardiol.2002; 40:238-44.
Doherty, D.E. et al. “Human Monocyte Adherence: A Primary Effect of Chemotactic Factors on the Monocyte to Stimulate Adherence to Human Endothelium”J. Immunol.138(6), 1762-1771, 1987.
Elgebaly, S.A., et al. “Cardiac Derived Neutrophil Chemotactic Factors; Preliminary Biochemical Characterization”J. Mol. Cell Cardiol., 21:585-593, 1989.
Elgebaly, S.A., et al. “Cyclocreatine Inhibits the Production of Neutrophil Chemotactic Factors from Isolated Hearts”Am J. Pathol.137: 1233-1241, 1990.
Elgebaly,J. Thorac. Cardiovasc. Surg, “Cardiac-derived neutrophil chemotactic factors: Detection in coronary sinus effluents of patients undergoing myocardial revascularization” 130(5): 952-959, 1992.
Elgebaly, S.A., et al. “Evidence of Cardiac Inflammation After Open Heart Operations”Ann. Thorac. Surg.57:391-396, 1994.
Joyce, “Amplification, mutation and selection of catalytic RNA” (1980),Gene82:83-87.
Kleinfeld, A.M., et al. “Increases in Serum Unbound Free Fatty Acid Levels Following Coronary Angioplasty”Am. J. Cardiol.1996: 78:1350-4.
Lucchesi, B.R., et al. “Leukocytes and Ischemia-induced Myocardial Injury”Annu Rev. Pharmacol. Toxicol.26, 201-224, 1986.
Newby, L.K., et al. “Bedside Multimarker Testing for Risk Stratification in Chest Pain Units”Circulation2001: 103; 1832-7.
Szostak et al. “In vitro selection of RNA molecules that bind specific ligands” (1990)Nature346: 818-822.
Tuerk et al. “Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase” (1990),Science249: 505-510.
Yamamoto, Yuri et al., “Inhibitory Effects of Spinorphin, a Novel Endogenous Regulator, on Chemotaxis, O2Generation, and Exocytosis by N-Formylmethionyl-leucyl-phenylalanine (FMLP)-Stimulated Neutrophils”Biochemical Pharmacology, 54; 695-701, 1997.
Beattie M.S., Trends in Molecular Medicine, 2004, vol. 19, No. 12, pp. 580-583.
Yamazaki et al., European Journal of Pharmacology, 2001, vol. 413, pp. 173-178.
O'Flaherthy et al., The Journal of Immunology, 1978, vol. 120, No. 4, pp. 1326-1332.
Le et al., Trends in Immunology, 2002, vol. 23, No. 11, pp. 541-548.
Lutsenko et al., Proc. Natl. Acad. Sci., 1998, vol. 95, pp. 6004-6009.
Koehler et al., Proc. Natl. Acad. Sci., 1999, vol. 96, pp. 2141-2146.
Haddad Maher M
Latimer & Mayberry IP Law LLP
Nourheart Inc.
LandOfFree
Diagnostic marker does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic marker, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic marker will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4194483